The majority of cases of EVI1 overexpression in hematologic malignancies do not occur in the context of translocations involving the MECOM locus, suggesting that aberrant epigenetic programming of the EVI1 promoter/enhancer elements is a more frequent driver of this oncogenic event. The gene discussed is MECOM; the disease is hematologic disorder.